Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed Primary Central Nervous System Lymphoma
NCT07185373Phase 3Recruiting
- Sponsor
- Huashan Hospital
- Start
- Oct 2025
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
A Phase 3 trial of orelabrutinib, teniposide in primary central nervous system lymphoma (PCNSL), sponsored by Huashan Hospital. Started Oct 2025; status: recruiting.
02
Drugs
orelabrutinibteniposide
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT07185373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07185373.